Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE 1 Trial? Seeking Alpha Research Peptide Spotlight: Calgri (Cagrilintide) is here! The long acting amylin analog that's blowing up in metabolic research. This powerhouse mimics your body's natural satiety hormone, helping dial down appetite and support Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet PDF] Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial. Semantic Scholar